AstraZeneca Appoints Aradhana Sarin As New Chief Financial Officer

AstraZeneca PLC announced that the Board has appointed Aradhana Sarin as an Executive Director and Chief Financial Officer, conditional upon closing of AstraZeneca’s acquisition of Alexion Pharmaceuticals, Inc. (Closing) and effective on the later of 1 August 2021 or the date of Closing, which is expected to take place in the third quarter of 2021, subject to receipt of certain regulatory approvals.

Dr. Sarin is currently Executive Vice-President, Chief Financial Officer of Alexion. Dr. Sarin will relocate from the US and be based in the UK.  She will report to AstraZeneca’s Chief Executive Officer, Pascal Soriot. 

Dr. Sarin will succeed Marc Dunoyer who will step down and retire from AstraZeneca’s Board after having served as CFO for over seven years. Conditional upon Closing and effective the same date as his retirement from AstraZeneca’s Board, Mr. Dunoyer will become Chief Executive Officer, Alexion and Chief Strategy Officer, AstraZeneca.  He will continue to report to Mr. Soriot and will remain a member of AstraZeneca’s Senior Executive Team.

Leif Johansson, Chairman of AstraZeneca said “On behalf of the Board, I’d like to thank Marc for his significant contribution to AstraZeneca’s success since he joined us in 2013.  We’re pleased he’s staying with the Company, taking on a new senior executive role and look forward to continuing to work with him.